FDA Approves Novavax COVID-19 Vaccine for Patients 65 Years and Older, Those With Underlying Conditions
The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.